Patrick Mercer - IRIDEX Chief Officer
| IRIX Stock | USD 1.77 0.03 1.67% |
Insider
Patrick Mercer is Chief Officer of IRIDEX
| Age | 52 |
| Address | 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043 |
| Phone | 650 940 4700 |
| Web | https://www.iridex.com |
Patrick Mercer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Patrick Mercer against IRIDEX stock is an integral part of due diligence when investing in IRIDEX. Patrick Mercer insider activity provides valuable insight into whether IRIDEX is net buyers or sellers over its current business cycle. Note, IRIDEX insiders must abide by specific rules, including filing SEC forms every time they buy or sell IRIDEX'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Patrick Mercer over two weeks ago Acquisition by Patrick Mercer of 200000 shares of IRIDEX subject to Rule 16b-3 | ||
Patrick Mercer over three months ago Disposition of tradable shares by Patrick Mercer of IRIDEX at 7.67 subject to Rule 16b-3 | ||
Patrick Mercer over three months ago Disposition of 4123 shares by Patrick Mercer of IRIDEX at 2.16 subject to Rule 16b-3 | ||
Patrick Mercer over six months ago Acquisition by Patrick Mercer of 120000 shares of IRIDEX subject to Rule 16b-3 |
IRIDEX Management Efficiency
The company has return on total asset (ROA) of (0.2089) % which means that it has lost $0.2089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5028) %, meaning that it created substantial loss on money invested by shareholders. IRIDEX's management efficiency ratios could be used to measure how well IRIDEX manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.21 in 2024. Return On Capital Employed is likely to rise to -0.28 in 2024. At this time, IRIDEX's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 4.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD MBA | Nutex Health | 51 | |
| Denise Pufal | Nutex Health | N/A | |
| Lawrence FACS | Nutex Health | 75 | |
| John Lorbiecki | Aclarion | 61 | |
| LaChoenda Rosales | Nutex Health | N/A | |
| Lakshmanan Kannappan | Healthcare Triangle | 57 | |
| Elizabeth Hall | Nutex Health | N/A | |
| Vivian MBA | Nutex Health | N/A | |
| Branislav Vajdic | Heartbeam | 69 | |
| BSN JD | Nutex Health | N/A | |
| Sudish Mogli | Healthcare Triangle | 55 | |
| Shibu Kizhakevilayil | Healthcare Triangle | 52 | |
| Suresh Venkatachari | Healthcare Triangle | 57 | |
| Thyagarajan Ramachandran | Healthcare Triangle | 48 | |
| Richard Brounstein | Heartbeam | 74 | |
| Jon Hunt | Heartbeam | 68 | |
| Michael Gill | Healthcare Triangle | 46 | |
| Wei Chen | EUDA Health Holdings | 39 | |
| Kristi Lane | Healthcare Triangle | N/A | |
| FACC MD | Heartbeam | 65 | |
| Ryan Bond | Aclarion | 52 | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.21 |
IRIDEX Leadership Team
Elected by the shareholders, the IRIDEX's board of directors comprises two types of representatives: IRIDEX inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IRIDEX. The board's role is to monitor IRIDEX's management team and ensure that shareholders' interests are well served. IRIDEX's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IRIDEX's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Bruce, CEO President | ||
| Leigh Salvo, Head Relations | ||
| Patrick Mercer, Chief Officer | ||
| Fuad Ahmad, Interim Officer | ||
| Scott JD, Executive Chairman |
IRIDEX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IRIDEX a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 30.99 M | ||||
| Shares Outstanding | 16.64 M | ||||
| Shares Owned By Insiders | 20.67 % | ||||
| Shares Owned By Institutions | 20.05 % | ||||
| Number Of Shares Shorted | 309.83 K | ||||
| Price To Earning | (6.30) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for IRIDEX Stock Analysis
When running IRIDEX's price analysis, check to measure IRIDEX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRIDEX is operating at the current time. Most of IRIDEX's value examination focuses on studying past and present price action to predict the probability of IRIDEX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRIDEX's price. Additionally, you may evaluate how the addition of IRIDEX to your portfolios can decrease your overall portfolio volatility.